皮膚がん診断および治療市場レポート：2030年までの動向、予測、競合分析

皮膚がん診断および治療の動向と予測

世界の皮膚がん診断および治療市場は、2024年から2030年までのCAGRが5.0%で、2030年までに推定181億米ドルに達すると予測されます。この市場の主な促進要因は、早期発見と皮膚がん治療に対する政府のイニシアチブの増加、皮膚がん診断薬および治療薬の研究開発活動の活発化、世界の皮膚がんの罹患率の増加と認知度の向上です。世界の皮膚がん診断および治療市場の将来は、診断および治療市場に機会があり、有望視されています。

皮膚がん診断および治療市場の洞察

Lucintelの予測では、非黒色腫の症例が増加していることから、予測期間中に非黒色腫が高い成長を遂げる見込みです。これらの皮膚がんは皮膚細胞から発生し、がん化（悪性化）したがん細胞群は近くの組織に増殖して破壊する可能性があります。

この市場では、治療が引き続き最大セグメントです。

北米では皮膚がんの有病率と発生率が高まっているため、予測期間中も最大セグメントであり続けると思われます。

本レポートでは、以下の11の主要な質問に回答している：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.今後成長が加速するセグメントとその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の皮膚がん診断および治療市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の皮膚がん診断および治療市場動向（2018-2023）および予測（2024-2030）
• がんタイプ別の世界の皮膚がん診断および治療市場
  • 黒色腫
  • 非黒色腫
• タイプ別の世界の皮膚がん診断および治療市場
  • 診断
  • 治療
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の皮膚がん診断および治療市場
• 北米の皮膚がん診断および治療市場
• 欧州の皮膚がん診断および治療市場
• アジア太平洋皮膚がん診断および治療市場
• その他地域皮膚がん診断および治療市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • がんタイプ別の世界の皮膚がん診断および治療市場の成長機会
  • タイプ別の世界の皮膚がん診断および治療市場の成長機会
  • 地域別の世界の皮膚がん診断および治療市場の成長機会
• 世界の皮膚がん診断および治療市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の皮膚がん診断および治療市場の能力拡大
  • 世界の皮膚がん診断・治療市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• AB Science
• Abbott Laboratories
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Castle Biosciences
• Daiichi Sankyo
• DAMAE Medical
• DermTech
• F. Hoffmann-La Roche

Skin Cancer Diagnostics & Therapeutics Trends and Forecast

The future of the global skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets. The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

A more than 150-page report is developed to help in your business decisions.

Skin Cancer Diagnostics & Therapeutics by Segment

The study includes a forecast for the global skin cancer diagnostics & therapeutics by cancer type, type, and region.

Skin Cancer Diagnostics & Therapeutics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Melanoma
• Non-Melanoma

Skin Cancer Diagnostics & Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Diagnosis
• Therapeutics
• Others

Skin Cancer Diagnostics & Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Skin Cancer Diagnostics & Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies skin cancer diagnostics & therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the skin cancer diagnostics & therapeutics companies profiled in this report include-

• Ab Science
• Abbott Laboratories
• Amgen
• Astrazeneca
• Bristol-Myers Squibb
• Castle Biosciences
• Daiichi Sankyo
• Damae Medical
• Dermtech
• F. Hoffmann-La Roche

Skin Cancer Diagnostics & Therapeutics Market Insights

Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Within this market, therapeutic will remain the largest segment.

North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Features of the Global Skin Cancer Diagnostics & Therapeutics Market

Market Size Estimates: Skin cancer diagnostics & therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Skin cancer diagnostics & therapeutics market size by cancer type, type, and region in terms of value ($B).

Regional Analysis: Skin cancer diagnostics & therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer types, types, and regions for the skin cancer diagnostics & therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the skin cancer diagnostics & therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the skin cancer diagnostics & therapeutics market size?

Answer: The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030.

Q.2 What is the growth forecast for skin cancer diagnostics & therapeutics market?

Answer: The global skin cancer diagnostics & therapeutics market is expected to grow with a cagr of 5.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the skin cancer diagnostics & therapeutics market?

Answer: The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

Q4. What are the major segments for skin cancer diagnostics & therapeutics market?

Answer: The future of the skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets.

Q5. Who are the key skin cancer diagnostics & therapeutics market companies?

Answer: Some of the key skin cancer diagnostics & therapeutics companies are as follows:

• AB Science
• Abbott Laboratories
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Castle Biosciences
• Daiichi Sankyo
• DAMAE Medical
• DermTech
• F. Hoffmann-La Roche

Q6. Which skin cancer diagnostics & therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Q7. In skin cancer diagnostics & therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the skin cancer diagnostics & therapeutics market by cancer type (melanoma and non-melanoma), type (diagnosis, therapeutics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Skin Cancer Diagnostics & Therapeutics Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Skin Cancer Diagnostics & Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Skin Cancer Diagnostics & Therapeutics Market by Cancer Type
  • 3.3.1: Melanoma
  • 3.3.2: Non-melanoma
• 3.4: Global Skin Cancer Diagnostics & Therapeutics Market by Type
  • 3.4.1: Diagnosis
  • 3.4.2: Therapeutics
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Skin Cancer Diagnostics & Therapeutics Market by Region
• 4.2: North American Skin Cancer Diagnostics & Therapeutics Market
  • 4.2.2: North American Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
• 4.3: European Skin Cancer Diagnostics & Therapeutics Market
  • 4.3.1: European Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
  • 4.3.2: European Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
• 4.4: APAC Skin Cancer Diagnostics & Therapeutics Market
  • 4.4.1: APAC Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
  • 4.4.2: APAC Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
• 4.5: ROW Skin Cancer Diagnostics & Therapeutics Market
  • 4.5.1: ROW Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
  • 4.5.2: ROW Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Cancer Type
  • 6.1.2: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Type
  • 6.1.3: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Region
• 6.2: Emerging Trends in the Global Skin Cancer Diagnostics & Therapeutics Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Skin Cancer Diagnostics & Therapeutics Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Skin Cancer Diagnostics & Therapeutics Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: AB Science
• 7.2: Abbott Laboratories
• 7.3: Amgen
• 7.4: AstraZeneca
• 7.5: Bristol-Myers Squibb
• 7.6: Castle Biosciences
• 7.7: Daiichi Sankyo
• 7.8: DAMAE Medical
• 7.9: DermTech
• 7.10: F. Hoffmann-La Roche